Economic issues involved in integrating genomic testing into clinical care: The case of genomic testing to guide decision-making about chemotherapy for breast cancer patients

Breast Cancer Research and Treatment

Volumn 129, Issue 2, 2011, Pages 401-409

  Marino, Patricia ^a,b,c   Siani, Carole ^d   Bertucci, François ^b,c,e,f   Roche, Henri ^g   Martin, Anne Laure ^h   Viens, Patrice ^b,c,e,f   Seror, Valérie ^a,b  

^a AIX MARSEILLE UNIV   (France)

^b AIX MARSEILLE UNIVERSITY   (France)

^c INSTITUT PAOLI CALMETTES   (France)

^d UNIVERSITÉ DE LYON   (France)

^e AIX MARSEILLE UNIVERSITY   (France)

^f Centre d'Analyses Protéomiques de Marseille   (France)

^g INSTITUT CLAUDIUS REGAUD   (France)

^h FNCLCC   (France)

Author keywords

Adjuvant chemotherapy; Breast cancer; Cost effectiveness; Genomic testing

Indexed keywords

CYCLOPHOSPHAMIDE; DNA; DOCETAXEL; EPIRUBICIN; FLUOROURACIL; ANTHRACYCLINE; ANTINEOPLASTIC AGENT; TAXOID;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER STAGING; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; COST MINIMIZATION ANALYSIS; DNA MICROARRAY; DRUG TARGETING; FEMALE; GENE EXPRESSION PROFILING; GENOME ANALYSIS; GENOTYPE; HEALTH CARE COST; HEALTH ECONOMICS; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MEATSTASIS FREE SURVIVAL; MEDICAL DECISION MAKING; MULTIPLE CYCLE TREATMENT; PATIENT GUIDANCE; PRIORITY JOURNAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); REIMBURSEMENT; RETROSPECTIVE STUDY; SURVIVAL; WELLBEING; ADJUVANT CHEMOTHERAPY; BREAST NEOPLASMS; CLINICAL TRIAL; COST BENEFIT ANALYSIS; DECISION MAKING; ECONOMICS; GENETIC SCREENING; GENETICS; MIDDLE AGED; MULTICENTER STUDY; RANDOMIZED CONTROLLED TRIAL;

ADULT; ANTHRACYCLINES; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; COST-BENEFIT ANALYSIS; DECISION MAKING; FEMALE; GENE EXPRESSION PROFILING; GENETIC TESTING; HUMANS; MIDDLE AGED; RETROSPECTIVE STUDIES; TAXOIDS;

EID: 80052635751     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-010-1242-z     Document Type: Article

References (39)

1. JC Davis L Furstenthal AA Desai T Norris S Sutaria E Fleming P Ma 2009 The microeconomics of personalized medicine: today's challenge and tomorrow's promise Nat Rev Drug Discov 8 4 279 286 19300459 10.1038/nrd2825 1:CAS:528:DC%2BD1MXjtlymsbc%3D
2. KA Phillips DL Veenstra SD Ramsey SL Van Bebber J Sakowski 2004 Genetic testing and pharmacogenomics: issues for determining the impact to healthcare delivery and costs Am J Manag Care 10 7 425 432 15298364 (Pubitemid 38970239)
3. D Houtsma HJ Guchelaar H Gelderblom 2010 Pharmacogenetics in oncology: a promising field Curr Pharm Des 16 2 155 163 20205661 10.2174/138161210790112719 1:CAS:528:DC%2BC3cXisVChtro%3D
4. S Vegter C Boersma M Rozenbaum B Wilffert G Navis MJ Postma 2008 Pharmacoeconomic evaluations of pharmacogenetic and genomic screening programmes: a systematic review on content and adherence to guidelines Pharmacoeconomics 26 7 569 587 18563949 10.2165/00019053-200826070-00005 1:CAS:528:DC%2BD1cXpslWqtbY%3D (Pubitemid 351871553)
5. PA Deverka 2009 Pharmacogenomics, evidence, and the role of payers Public Health Genomics 12 3 149 157 19204417 10.1159/000189627 1:STN:280: DC%2BD1M7jtVShug%3D%3D
6. Drummond M, O'Brien B, Stoddart G (1997) Methods for the economic evaluation of health care programs, 2nd edn. Oxford Medical Publications, Oxford University Press, New York
7. BJ Evans 2007 Distinguishing product and practice regulation in personalized medicine Clin Pharmacol Ther 81 2 288 293 17259953 10.1038/sj.clpt.6100042 1:STN:280:DC%2BD2s%2FovVamtw%3D%3D (Pubitemid 46174827)
8. LJ van't Veer H Dai MJ van de Vijver YD He AA Hart M Mao HL Peterse K van der Kooy MJ Marton AT Witteveen, et al. 2002 Gene expression profiling predicts clinical outcome of breast cancer Nature 415 6871 530 536 10.1038/415530a (Pubitemid 34130608)
9. MJ van de Vijver YD He LJ van't Veer H Dai AA Hart DW Voskuil GJ Schreiber JL Peterse C Roberts MJ Marton, et al. 2002 A gene-expression signature as a predictor of survival in breast cancer N Engl J Med 347 25 1999 2009 12490681 10.1056/NEJMoa021967 (Pubitemid 35461656)
10. F Bertucci P Finetti N Cervera D Maraninchi P Viens D Birnbaum 2006 Gene expression profiling and clinical outcome in breast cancer Omics 10 4 429 443 17233555 10.1089/omi.2006.10.429 1:CAS:528:DC%2BD2sXmsVaguw%3D%3D (Pubitemid 46174577)
11. F Bray R Sankila J Ferlay DM Parkin 2002 Estimates of cancer incidence and mortality in Europe in 1995 Eur J Cancer 38 1 99 166 11750846 10.1016/S0959-8049(01)00350-1 1:STN:280:DC%2BD38%2Fgt1yitw%3D%3D (Pubitemid 34031832)
12. Early Breast Cancer Trialists' Cooperative Group 2005 Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials Lancet 365 9472 1687 1717 10.1016/S0140-6736(05)66544-0 (Pubitemid 40719106)
13. MJ Piccart D de Valeriola L Dal Lago E de Azambuja G Demonty F Lebrun C Bernard-Marty M Colozza T Cufer 2005 Adjuvant chemotherapy in 2005: standards and beyond Breast 14 6 439 445 16188441 10.1016/j.breast.2005.08.004 1:STN:280:DC%2BD2MnltVenuw%3D%3D (Pubitemid 41683564)
14. EP Mamounas J Bryant B Lembersky L Fehrenbacher SM Sedlacek B Fisher DL Wickerham G Yothers A Soran N Wolmark 2005 Paclitaxel after doxorubicin plus cyclophosphamide as adjuvant chemotherapy for node-positive breast cancer: results from NSABP B-28 J Clin Oncol 23 16 3686 3696 15897552 10.1200/JCO.2005.10.517 1:CAS:528:DC%2BD2MXlslWntrw%3D
15. M Martin T Pienkowski J Mackey M Pawlicki JP Guastalla C Weaver E Tomiak T Al-Tweigeri L Chap E Juhos, et al. 2005 Adjuvant docetaxel for node-positive breast cancer N Engl J Med 352 22 2302 2313 15930421 10.1056/NEJMoa043681 1:CAS:528:DC%2BD2MXksl2lt7c%3D (Pubitemid 40740554)
16. H Roche P Fumoleau M Spielmann JL Canon T Delozier D Serin M Symann P Kerbrat P Soulie F Eichler, et al. 2006 Sequential adjuvant epirubicin-based and docetaxel chemotherapy for node-positive breast cancer patients: the FNCLCC PACS 01 Trial J Clin Oncol 24 36 5664 5671 17116941 10.1200/JCO.2006.07.3916 1:CAS:528:DC%2BD2sXhtVChs78%3D (Pubitemid 46631307)
17. AU Buzdar SE Singletary V Valero DJ Booser NK Ibrahim Z Rahman RL Theriault R Walters E Rivera TL Smith, et al. 2002 Evaluation of paclitaxel in adjuvant chemotherapy for patients with operable breast cancer: preliminary data of a prospective randomized trial Clin Cancer Res 8 5 1073 1079 12006521 1:CAS:528:DC%2BD38XksVSqu78%3D (Pubitemid 34517642)
18. E Bria C Nistico F Cuppone P Carlini M Ciccarese M Milella G Natoli E Terzoli F Cognetti D Giannarelli 2006 Benefit of taxanes as adjuvant chemotherapy for early breast cancer: pooled analysis of 15,500 patients Cancer 106 11 2337 2344 16649217 10.1002/cncr.21886 1:CAS:528:DC%2BD28Xls1Srur0%3D (Pubitemid 43787656)
19. M Campone P Fumoleau E Bourbouloux P Kerbrat H Roche 2005 Taxanes in adjuvant breast cancer setting: which standard in Europe? Crit Rev Oncol Hematol 55 3 167 175 16039867 10.1016/j.critrevonc.2005.04.003 (Pubitemid 41219689)
20. DL Veenstra MK Higashi KA Phillips 2000 Assessing the cost-effectiveness of pharmacogenomics AAPS PharmSci 2 3 E29 11741245 10.1208/ps020329 1:STN:280:DC%2BD3MjgtVOisA%3D%3D
21. CR Flowers D Veenstra 2004 The role of cost-effectiveness analysis in the era of pharmacogenomics Pharmacoeconomics 22 8 481 493 15217305 10.2165/00019053-200422080-00001 (Pubitemid 38858292)
22. AE Guttmacher FS Collins 2002 Genomic medicine-a primer N Engl J Med 347 19 1512 1520 12421895 10.1056/NEJMra012240 1:CAS:528:DC%2BD38XosVOnsL0%3D (Pubitemid 35257592)
23. F Bertucci V Nasser S Granjeaud F Eisinger J Adelaide R Tagett B Loriod A Giaconia A Benziane E Devilard, et al. 2002 Gene expression profiles of poor-prognosis primary breast cancer correlate with survival Hum Mol Genet 11 8 863 872 11971868 10.1093/hmg/11.8.863 1:CAS:528:DC%2BD38XjtlGksbY%3D (Pubitemid 34449774)
24. Bertucci F, Borie N, Roche H, Bachelot T, Le Doussal JM, Macgrogan G, Debono S, Martinec A et al (2010) Gene expression profile predicts outcome after anthracycline-based adjuvant chemotherapy in early breast cancer. Breast Cancer Res Treat. doi: 10.1007/s10549-010-1003-z
25. Marino P, Siani C, Roché H, Protière C, Fumoleau P, Spielmann M, Martin A-L, Viens P, Le Corroller Soriano A-G (2010) Cost-effectiveness of adjuvant docetaxel for node-positive breast cancer patients: results of the PACS 01 economic study. Ann Oncol 21(7):1448-1454
26. SA Finkler 1982 The distinction between cost and charges Ann Intern Med 96 1 102 109 7053682 1:STN:280:DyaL38%2FovFGlsA%3D%3D
27. AH Sims KR Ong RB Clarke A Howell 2006 High-throughput genomic technology in research and clinical management of breast cancer. Exploiting the potential of gene expression profiling: is it ready for the clinic? Breast Cancer Res 8 5 214 17076877 10.1186/bcr1605 (Pubitemid 44803997)
28. DM Roden RB Altman NL Benowitz DA Flockhart KM Giacomini JA Johnson RM Krauss HL McLeod MJ Ratain MV Relling, et al. 2006 Pharmacogenomics: challenges and opportunities Ann Intern Med 145 10 749 757 17116919 (Pubitemid 351650355)
29. JJ Swen TW Huizinga H Gelderblom EG de Vries WJ Assendelft J Kirchheiner HJ Guchelaar 2007 Translating pharmacogenomics: challenges on the road to the clinic PLoS Med 4 8 e209 17696640 10.1371/journal.pmed.0040209 (Pubitemid 47358167)
30. JS Ross C Hatzis WF Symmans L Pusztai GN Hortobagyi 2008 Commercialized multigene predictors of clinical outcome for breast cancer Oncologist 13 5 477 493 18515733 10.1634/theoncologist.2007-0248 (Pubitemid 351872866)
31. GH Lyman NM Kuderer 2006 Gene expression profile assays as predictors of recurrence-free survival in early-stage breast cancer: a metaanalysis Clin Breast Cancer 7 5 372 379 17239261 10.3816/CBC.2006.n.053 (Pubitemid 46157557)
32. J Hornberger LE Cosler GH Lyman 2005 Economic analysis of targeting chemotherapy using a 21-gene RT-PCR assay in lymph-node-negative, estrogen-receptor-positive, early-stage breast cancer Am J Manag Care 11 5 313 324 15898220 (Pubitemid 40646936)
33. GH Lyman LE Cosler NM Kuderer J Hornberger 2007 Impact of a 21-gene RT-PCR assay on treatment decisions in early-stage breast cancer: an economic analysis based on prognostic and predictive validation studies Cancer 109 6 1011 1018 17311307 10.1002/cncr.22506 (Pubitemid 46435378)
34. N Oestreicher SD Ramsey HM Linden JS McCune LJ van't Veer W Burke DL Veenstra 2005 Gene expression profiling and breast cancer care: what are the potential benefits and policy implications? Genet Med 7 6 380 389 16024969 10.1097/01.GIM.0000170776.31248.75 (Pubitemid 41139621)
35. Chen MK, Nalebuff B (2006) One-way essential complements. Cowles Foundation Discussion Paper, vol 1588, Yale University
36. J Gabszewicz N Sonnac X Wauthy 2001 On price competition with complementary goods Econ Lett 70 3 431 437 10.1016/S0165-1765(00)00383-9
37. RA Hirth ME Chernew E Miller AM Fendrick WG Weissert 2000 Willingness to pay for a quality-adjusted life year: in search of a standard Med Decis Making 20 3 332 342 10929856 10.1177/0272989X0002000310 1:STN:280: DC%2BD3M%2FjvVOnsA%3D%3D (Pubitemid 30479101)
38. JL Pinto-Prades G Loomes R Brey 2009 Trying to estimate a monetary value for the QALY J Health Econ 28 3 553 562 19327857 10.1016/j.jhealeco.2009.02.003
39. H Mason M Jones-Lee C Donaldson 2009 Modelling the monetary value of a QALY: a new approach based on UK data Health Econ 18 8 933 950 18855880 10.1002/hec.1416